News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Subscribe To Our Newsletter & Stay Updated
